SCHEMBL1344879

SCHEMBL1344879

FC(F)(F)c1ccc(Nc2nnc(-c3ccsc3Cc3ccnc4ccccc34)s2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
CTDSP1 Q9GZU7 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
NPY5R Q15761 1/20 0.38
SYK P43405 1/20 0.38
PIK3CD O00329 1/20 0.37
PIK3CA P42336 1/20 0.37
PIK3CB P42338 1/20 0.37
ABCG2 Q9UNQ0 2/20 0.35
KDR P35968 5/20 0.35
RAF1 P04049 1/20 0.35
LCK P06239 1/20 0.35
RET P07949 1/20 0.35
CYP3A4 P08684 1/20 0.35
KIT P10721 1/20 0.35
MAP3K20 Q9NYL2 1/20 0.35
RIPK3 Q9Y572 1/20 0.35
EPHX2 P34913 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1346741 0.89 MAPT (0.39) MEN1RAB9AKMT2APIK3CDPIK3CA
SCHEMBL1346570 0.81 FADS1 (0.48) MEN1RAB9AKMT2ATDP1ABCG2
SCHEMBL1344964 0.80 SYK (0.38) MEN1KMT2ACTDSP1NPY5RSYK
SCHEMBL1344874 0.79 MEN1 (0.41) MEN1RAB9AKMT2ACTDSP1TDP1
SCHEMBL1346459 0.73 NR3C2 (0.45) SYKMAPT
SCHEMBL1346555 0.72 KDR (0.61) RAB9AABCG2KDRFLT1
SCHEMBL1346772 0.72 MEN1 (0.46) MEN1KMT2APIK3CDPIK3CAPIK3CB
SCHEMBL1346719 0.71 FLT1 (0.47) MEN1RAB9AKMT2ACTDSP1TDP1
SCHEMBL13604327 0.70 MEN1 (0.45) MEN1RAB9AKMT2APIK3CDPIK3CA
SCHEMBL1344703 0.69 KDR (0.41) MEN1KMT2ACTDSP1SYKPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063034-B2 Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-11-22 US claimed
US-20100016354-A1 NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY SANTEN PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US claimed
EP-2128156-A1 NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITING ACTIVITY Santen Pharmaceutical Co., Ltd (JP) 2009-12-02 EP claimed
US-8063034-B2 Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-11-22 US disclosed
US-20100016354-A1 NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY SANTEN PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128156-A1 NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITING ACTIVITY Santen Pharmaceutical Co., Ltd (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016354-A1 NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY FLT4, VEGFA, FLT1 MEN1 4661/4885RAB9A 2350/4885KMT2A 4259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.